SCHEDULE: Fresenius Medical Care Adjusts Humacyte Stake Disclosure

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have filed an amendment to their Schedule 13D, updating their beneficial ownership of Humacyte, Inc. common stock to 6.8%.

Summary

• This filing is an amendment (Amendment No. 9) to a previously filed Schedule 13D concerning the beneficial ownership of Humacyte, Inc. common stock by Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG).
• The amendment updates the beneficial ownership percentage to 6.8% of Humacyte's outstanding shares, down from a previous 8.4%.
• This decrease in percentage ownership is attributed solely to an increase in the total number of Humacyte's outstanding shares, not to any sale or purchase of shares by FMCH or FME AG.
• FMCH directly owns 18,312,735 shares of Humacyte's common stock, which represents the reported 6.8% beneficial ownership.
• FME AG is the indirect sole shareholder of FMCH and may be deemed a beneficial owner of these shares.
• The filing also notes the appointment of Ms. Mollie Miller as Vice President and Assistant Treasurer of FMCH, effective May 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It's a routine disclosure amendment reflecting changes in share count rather than a strategic shift or new development from Fresenius Medical Care or Humacyte.

Positives

• Fresenius Medical Care Holdings, Inc. continues to hold a significant stake in Humacyte, Inc., indicating ongoing strategic interest.
• The decrease in ownership percentage is due to an increase in outstanding shares, not a disposition of shares by Fresenius, preserving their investment.
• The appointment of Mollie Miller as VP and Assistant Treasurer suggests continued operational management within Fresenius Medical Care Holdings, Inc.

Negatives

• The dilution of Fresenius's ownership percentage from 8.4% to 6.8% means their relative control or influence may be reduced.
• The filing does not provide specific reasons for the increase in Humacyte's outstanding shares, which could be due to further equity issuances that dilute existing shareholders.

Risks

• The decrease in percentage ownership could signal a reduced strategic commitment or a need for Fresenius to acquire more shares to maintain influence.
• The increase in Humacyte's outstanding shares, leading to dilution, could negatively impact the value of existing holdings if not accompanied by proportional growth in company value.

Future Outlook

The filing itself is an update to a previous disclosure and does not contain forward-looking statements or guidance regarding Humacyte, Inc.'s future performance. It primarily serves to report changes in beneficial ownership percentages due to share count fluctuations.

Management Comments

• "Except as provided herein, this Amendment No. 9 does not modify any of the information previously reported on the Schedule 13D."
• "The decrease in the percentage beneficial ownership reported herein from 8.4% as reported in Schedule 13D (Amendments Nos. 7 and 8) to 6.8%, as reported herein, results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 8 to this Schedule 13D."
• "Neither FME AG nor FMCH has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of their initial Schedule 13D in September 2021."
• "All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH."
• "Such 18,312,735 shares of Common Stock exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement described in the initial Schedule 13D, and FME AG and FMCH disclaim any present beneficial ownership of any such additional shares."

Industry Context

StockSavvy.ai notes that this filing reflects a common occurrence in the biotechnology and healthcare sectors where companies, especially those in earlier stages of development or commercialization, may issue additional shares to fund operations, research, or expansion. This can lead to dilution for existing significant shareholders like Fresenius Medical Care, necessitating adjustments in reporting and potentially signaling a need for further capital raises by the issuer.

Management Changes

Stakeholder Impact

• Shareholders of Humacyte, Inc.: The increase in outstanding shares dilutes the ownership percentage of all existing shareholders, including Fresenius Medical Care, potentially impacting their proportional voting power and claim on future earnings.
• Fresenius Medical Care AG and FMCH: Their relative ownership stake has decreased, which could affect their influence over Humacyte's strategic decisions, although they have not sold any shares.
• Creditors of Humacyte, Inc.: If the increase in shares is for capital raising, it could strengthen the company's financial position, potentially benefiting creditors. However, significant dilution without corresponding value creation could be a long-term concern.

Next Steps

• Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG will continue to monitor their beneficial ownership percentage in Humacyte, Inc. and file amendments to Schedule 13D as required by SEC regulations.
• Humacyte, Inc. may continue to issue shares for financing or strategic purposes, potentially leading to further dilution for existing shareholders.

Key Dates

Keywords

Humacyte, Fresenius Medical Care, Schedule 13D, Beneficial Ownership, SEC Filing, Amendment, Common Stock, Dilution, Corporate Governance